AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2014
Jan 24, 2014
33422_dirs_2014-01-24_42b91ed5-2840-450e-9d71-af4123f46125.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2014-01-21
Reporting Person: CZIRR JAMES C (Director, Executive Chairman)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-01-21 | Stock Option (Right to Buy) | $13.38 | A | 61000 | Acquired | 2024-01-21 | Common Stock (61000) | Direct |
Footnotes
F1: 25% of the options vested upon grant date, with the remainder vesting ratably on a monthly basis over a three year period.
More from GALECTIN THERAPEUTICS INC
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21